

# CITATION REPORT

List of articles citing

**Rapamune (Sirolimus, rapamycin): an overview and mechanism of action**

**DOI: 10.1097/00007691-199512000-00019**  
**Therapeutic Drug Monitoring, 1995, 17, 660-5.**

**Source:** <https://exaly.com/paper-pdf/25782235/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
259	Comparison of binding characteristics of four rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity measured by the mixed-lymphocyte culture assay. <b>1996</b> , 29, 309-13		14
258	Monitoring new immunosuppressive agents. Are the methods adequate?. <b>1997</b> , 14, 5-15		13
257	Xenogeneic transplantation. <b>1997</b> , 53, 904-20		17
256	Clinically significant drug interactions with new immunosuppressive agents. <b>1997</b> , 16, 267-78		87
255	Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. <b>1997</b> , 79, 138-47		41
254	Clinical chemistry and post-liver-transplant monitoring. <b>1997</b> , 43, 1546-1554		33
253	Detection and quantification of cyclosporine in body fluids using an interleukin-2 reporter-gene assay. <b>1997</b> , 201, 125-35		6
252	Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. <b>1998</b> , 43, 2227-36		26
251	Biochemical approaches to discovering modulators of the JAK/STAT pathway. <b>1998</b> , 3, 122-130		21
250	The Influence of Some Immunosuppressive Drugs on the Metabolic Activity of Human Phagocytes and Lymphocytes in vitro. <b>1998</b> , 11, 155-162		6
249	Calcineurin is required for skeletal muscle hypertrophy. <b>1999</b> , 274, 21908-12		202
248	Pharmacokinetic and pharmacodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. <b>1999</b> , 27, 1-21		7
247	The insulin signaling pathway. <b>1999</b> , 169, 1-12		136
246	Requirement for phosphatidylinositol-3-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. <b>1999</b> , 140, 941-9		92
245	Promising new agents in the prevention of transplant rejection. <b>1999</b> , 1, 55-60		10
244	Guidelines for immunosuppression management and monitoring after transplantation in children. <b>1999</b> , 13, 83-97		3
243	Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. <b>1999</b> , 117, 1198-204		169

242	Theory and practice of cytokine assessment in immunotoxicology. <b>1999</b> , 19, 17-27		32
241	Maintenance immunosuppression: new agents and persistent dilemmas. <b>2000</b> , 7, 95-116		23
240	Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. <b>2000</b> , 8, 52-62		45
239	Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. <i>Transplantation</i> , <b>2000</b> , 70, 1244-7	1.8	95
238	Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 608-12	3.2	42
237	Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide. <b>2000</b> , 35, 454-60		9
236	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. <b>2000</b> , 19, 6680-6		520
235	Drug therapy for acute graft-versus-host disease prophylaxis. <b>2000</b> , 9, 317-25		20
234	Validation of an Assay for Routine Monitoring of Sirolimus Using HPLC with Mass Spectrometric Detection. <b>2000</b> , 46, 1179-1183		74
233	Sirolimus: a new agent for prevention of renal allograft rejection. <b>2000</b> , 57, 437-48; quiz 449-51		69
232	Sirolimus: continuing the evolution of transplant immunosuppression. <b>2000</b> , 34, 1044-55		47
231	Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. <b>2000</b> , 22 Suppl B, B38-48		48
230	An immunoassay for the measurement of sirolimus. <b>2000</b> , 22 Suppl B, B49-61		46
229	The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. <b>2000</b> , 22 Suppl B, B71-85		45
228	Immunosuppressive therapies for the twenty-first century. <b>2000</b> , 32, 1463-7		9
227	Sirolimus (rapamycin) in clinical transplantation. <b>2001</b> , 15, 165-177		11
226	Rescue therapy: a role for sirolimus in lung and heart transplant recipients. <b>2001</b> , 33, 1084-5		34
225	Phase III trial of Rapamune versus placebo in primary renal allograft recipients. <b>2001</b> , 33, 2271-2		20

224	RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. <b>2001</b> , 33, 2320-1		9
223	Interaction of immunophilin-binding immunosuppressives with the glucocorticoid receptor signaling pathway: implications for transplantation. <b>2001</b> , 33, 2417-9		0
222	The evolving role of tor inhibitors for individualizing posttransplant immunosuppression. <b>2001</b> , 33, 3075-7		6
221	Refining immunosuppressive protocols in pediatric renal transplant recipients. <b>2001</b> , 33, 3587-9		10
220	Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. <i>Transplantation</i> , <b>2001</b> , 72, 777-86	1.8	365
219	Pathogenesis and prevention of graft-versus-host disease. <i>Current Opinion in Organ Transplantation</i> , <b>2001</b> , 6, 265-271	2.5	6
218	Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. <i>Transplantation</i> , <b>2001</b> , 71, 160-3	1.8	32
217	Regulatory mechanisms of female germ cell apoptosis during embryonic development. <b>2001</b> , 48, 289-301		6
216	Rapamycin in transplantation: a review of the evidence. <b>2001</b> , 59, 3-16		327
215	Tailoring immunosuppressive therapy for renal transplant recipients. <b>2001</b> , 5, 467-72		16
214	Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. <b>2001</b> , 44, 2027-34		58
213	Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat. <b>2001</b> , 46, 2120-6		10
212	Regulated gene expression in gene therapy. <b>2001</b> , 953, 53-63		17
211	Inhibition of p70(S6) kinase during transforming growth factor-beta 1/vitamin D(3)-induced monocyte differentiation of HL-60 cells allows tumor necrosis factor-alpha to stimulate plasminogen activator inhibitor-1 synthesis. <b>2001</b> , 276, 32214-9		10
210	Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. <b>2001</b> , 166, 7165-71		87
209	Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle. <b>2001</b> , 166, 5611-8		43
208	New developments in the prophylaxis and treatment of graft versus host disease. <b>2001</b> , 2, 1109-17		19
207	Novel therapeutics for the treatment of graft-versus-host disease. <b>2002</b> , 11, 1271-80		23

206	A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 346-50	3.2	78
205	Sirolimus (Rapamune) in renal transplantation. <b>2002</b> , 11, 603-7		33
204	Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. <i>Transplantation</i> , <b>2002</b> , 74, 1560-7	1.8	142
203	Axonal regeneration after cold preservation of nerve allografts and immunosuppression with tacrolimus in mice. <b>2002</b> , 96, 924-32		60
202	Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. <b>2002</b> , 62, 879-89		43
201	Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. <b>2002</b> , 359, 619-22		58
200	Sirolimus-based steroid-free maintenance immunosuppression. <b>2002</b> , 34, 1709-10		8
199	Sirolimus and tacrolimus in clinical cardiac transplantation. <b>2002</b> , 34, 1839-42		7
198	Updating renal transplantation therapies in developing countries. <b>2002</b> , 34, 2475-7		2
197	Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. <b>2002</b> , 21, 540-6		105
196	Strategies to reduce toxicities and improve outcomes in renal transplant recipients. <b>2002</b> , 22, 316-28		15
195	FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. <b>2002</b> , 437, 123-8		27
194	Sirolimus-eluting stents: a review of experimental and clinical findings. <b>2002</b> , 91 Suppl 3, 49-57		19
193	Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. <b>2002</b> , 6, 147-52		24
192	Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. <b>2002</b> , 54, 65-8		13
191	Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. <b>2002</b> , 136, 604-12		14
190	Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. <b>2003</b> , 9, 1079-85		107
189	The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. <b>2003</b> , 3, 497-500		16

188	Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. <b>2003</b> , 3, 416-23	144
187	Sirolimus and mycophenolate mofetil after liver transplantation. <b>2003</b> , 16, 504-509	30
186	BiCore hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. <b>2003</b> , 35, 58S-61S	24
185	Ten years of sirolimus therapy in orthotopic liver transplant recipients. <b>2003</b> , 35, 209S-216S	58
184	Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. <b>2003</b> , 35, 89S-94S	7
183	How should sirolimus be used in clinical practice?. <b>2003</b> , 35, 79S-83S	2
182	Sirolimus experience at a Swedish transplantation center. <b>2003</b> , 35, 84S-88S	3
181	Conversion to sirolimus in solid organ transplantation: a single-center experience. <b>2003</b> , 35, 131S-137S	52
180	Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. <b>2003</b> , 35, 52S-57S	82
179	Sirolimus in heart transplantation: a single center initial experience. <b>2003</b> , 35, 1978-80	7
178	Sirolimus: a potential option for the prevention of chronic allograft nephropathy. <b>2003</b> , 17, 11-19	
177	Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. <b>2003</b> , 17, 20-30	3
176	New Antiproliferative Immunosuppressive Agents. <b>2003</b> , 16, 401-413	
175	The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. <b>2003</b> , 3, 211-30	28
174	Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. <b>2003</b> , 349, 847-58	925
173	The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. <b>2003</b> , 24, 154-8; discussion 158	21
172	Signal transduction--directed cancer treatments. <b>2003</b> , 43, 199-231	76
171	Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family. <b>2003</b> , 100, 14253-8	38

170	Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. <b>2003</b> , 3, 1315-47		306
169	The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. <i>Transplantation</i> , <b>2003</b> , 75, 772-80	1.8	31
168	Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. <b>2003</b> , 43, 1168-76		46
167	Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. <i>Transplantation</i> , <b>2003</b> , 76, 1594-9	1.8	58
166	A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. <i>Transplantation</i> , <b>2003</b> , 75, 1404-8	1.8	62
165	Everolimus in pediatric de nova renal transplant patients. <i>Transplantation</i> , <b>2003</b> , 75, 2082-5	1.8	49
164	Emerging therapies for graft-versus-host disease. <b>2003</b> , 8, 323-38		12
163	Anti-cytokine therapy for the treatment of graft-versus-host disease. <b>2004</b> , 10, 1195-205		38
162	FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. <b>2004</b> , 279, 772-8		127
161	Novel immunosuppressants. <b>2004</b> , 8, 594-9		16
160	Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia. <b>2004</b> , 17, 9-14		14
159	Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. <b>2004</b> , 17, 279-285		26
158	Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. <b>2004</b> , 4, 626-35		207
157	Sirolimus in Kidney Transplantation: A Pilot Study in Chinese Patients. <b>2004</b> , 6, 38-42		1
156	Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. <b>2004</b> , 49, 30-7		19
155	Effect of sirolimus on infection incidence in liver transplant recipients. <b>2004</b> , 10, 193-8		27
154	Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. <b>2004</b> , 18, 315-28		47
153	Clinical pharmacokinetics of everolimus. <b>2004</b> , 43, 83-95		352

152	Exposure-response relationships and drug interactions of sirolimus. <b>2004</b> , 6, e28		155
151	Spotlight on the sirolimus-eluting stent in coronary artery disease. <b>2004</b> , 2, 69-73		
150	Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. <b>2004</b> , 23, 780-2		29
149	Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. <b>2004</b> , 36, 274S-284S		16
148	Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment. <b>2004</b> , 36, 1547-50		8
147	Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. <b>2004</b> , 23, 770-3		25
146	Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. <i>Transplantation</i> , <b>2004</b> , 78, 338-44	1.8	44
145	Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. <i>Transplantation</i> , <b>2004</b> , 78, 475-80	1.8	37
144	A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. <i>Transplantation</i> , <b>2004</b> , 78, 264-8	1.8	98
143	A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. <i>Transplantation</i> , <b>2005</b> , 80, 303-9	1.8	115
142	Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. <i>Transplantation</i> , <b>2005</b> , 80, 1212-9	1.8	73
141	Calcineurin inhibitor-free immunosuppression after heart transplantation: can chronic side effects be avoided?. <i>Current Opinion in Organ Transplantation</i> , <b>2005</b> , 10, 360-363	2.5	3
140	Proliferation signal inhibitors: a new substance class in immunosuppression after heart transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>2005</b> , 10, 355-359	2.5	1
139	Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. <b>2005</b> , 67, 1471-5		32
138	Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. <b>2005</b> , S69-73		17
137	Cardiac tamponade in a pediatric renal transplant recipient on sirolimus therapy. <b>2005</b> , 9, 541-4		12
136	Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. <b>2005</b> , 18, 151-6		22
135	Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. <b>2005</b> , 18, 1028-35		49



134	Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. <b>2005</b> , 130, 409-17	159
133	Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. <b>2005</b> , 5, 2521-30	175
132	Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. <b>2005</b> , 5, 2799-804	41
131	Current status of mammalian target of rapamycin inhibitors in lung cancer. <b>2005</b> , 7 Suppl 1, S13-8	12
130	Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. <b>2005</b> , 34, 119-26	53
129	Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. <b>2005</b> , 37, 795-7	35
128	Cancer du sein. <b>2006</b> ,	
127	Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. <b>2006</b> , 38, 3520-3	36
126	Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. <b>2006</b> , 38, 3476-8	16
125	Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 51-61	3,2 21
124	SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. <b>2006</b> , 10, 593-601	28
123	Rapamycin induces a caspase-independent cell death in human monocytes. <b>2006</b> , 6, 1331-41	22
122	Mycophenolate mofetil and sirolimus combination in renal transplantation. <b>2006</b> , 6, 1991-9	53
121	Immunosuppressive drugs in HIV disease. <b>2006</b> , 6, 1769-89	21
120	A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. <b>2006</b> , 12, 5755-63	191
119	Cancer du sein. <b>2007</b> ,	2
118	Molecular pathogenesis of lymphangioliomyomatosis: lessons learned from orphans. <b>2007</b> , 36, 398-408	78
117	Is sirolimus a nephrotoxic drug? A report of five cases. <b>2007</b> , 39, 1406-9	4

116	An assay for the determination of sirolimus levels in the lymphocyte of transplant patients. <b>2007</b> , 39, 1204-6	10
115	Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. <b>2007</b> , 195, 23-30	33
114	In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. <b>2007</b> , 35, 1554-63	34
113	Liver transplantation(). <b>2007</b> , 10, 28-45	5
112	Comparison of the CEDIA and MEIA assays for the measurement of sirolimus in organ transplant recipients. <b>2007</b> , 40, 680-7	5
111	12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. <b>2007</b> , 20, 27-36	81
110	Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. <b>2007</b> , 21, 377-84	30
109	Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemia-reperfusion injury. <b>2007</b> , 7, 48-56	16
108	High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin's lymphoma. <b>2007</b> , 79, 155-8	9
107	mTOR signalling in human cancer. <b>2007</b> , 9, 484-93	51
106	Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. <b>2008</b> , 14, 651-9	51
105	A combination of donor specific transfusion and rapamycin prolongs cardiac allograft survival in mice. <b>2008</b> , 40, 3699-701	6
104	Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice. <b>2008</b> , 38, 1130-9	13
103	The potential role of mTOR inhibitors in non-small cell lung cancer. <b>2008</b> , 13, 139-47	98
102	Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. <i>Transplantation</i> , <b>2008</b> , 85, 821-6	1.8 90
101	The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway. <b>2008</b> , 49, 592-600	17
100	Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. <b>2009</b> , 1, 42-9	12
99	Improved outcome with immunosuppressive monotherapy after renal transplantation in Schimke-immuno-osseous dysplasia. <b>2009</b> , 13, 482-9	7

98	Pharmaceutical Perspectives of Cancer Therapeutics. <b>2009</b> ,		11
97	Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. <b>2009</b> , 41, 2095-8		1
96	Targeted Therapies for Malignant Brain Tumors. <b>2009</b> , 475-519		
95	Pediatric Chronic Graft versus Host Disease. 369-385		1
94	Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. <i>Transplantation</i> , <b>2009</b> , 88, 421-8	1.8	52
93	Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. <i>Transplantation</i> , <b>2010</b> , 89, 1511-7	1.8	50
92	Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats. <b>2010</b> , 55, 2255-62		15
91	Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. <b>2010</b> , 23, 26-32		8
90	Future outlook for drug eluting stents. <b>2010</b> , 117-153		1
89	Kidney Transplantation: A Guide to the Care of Kidney Transplant Recipients. <b>2010</b> ,		1
88	Chronic graft-versus-host disease (GVHD) in children. <b>2010</b> , 57, 297-322		87
87	NRPS/PKS Hybrid Enzymes and Their Natural Products. <b>2010</b> , 453-492		4
86	Evaluation of a fully automated method for the determination of sirolimus. <b>2010</b> , 42, 3044-6		1
85	Anaemia, microcytosis and sirolimus--is iron the missing link?. <b>2010</b> , 25, 1667-75		37
84	Lymphangioliomyomatosis. <b>2011</b> , 47, 85-93		
83	Lymphangioliomyomatosis. <b>2011</b> , 47, 85-93		11
82	ClickSynthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics. <b>2011</b> , 19, 6167-73		32
81	Subconjunctival sirolimus in the treatment of diabetic macular edema. <b>2011</b> , 249, 1627-33		32

80	An evaluation of sirolimus in renal transplantation. <b>2012</b> , 8, 1337-56		23
79	Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. <b>2012</b> , 18, 2534-44		45
78	Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. <i>Transplantation</i> , <b>2012</b> , 93, 1006-12	1.8	17
77	Nobori® drug-eluting stent system: current data on a novel stent. <b>2012</b> , 4, 309-318		
76	Effects of Liver Disease on Drug Metabolism in Humans. <b>2012</b> , 1		1
75	Influence of sirolimus-loaded nanoparticles on physiological functions of native human polymorphonuclear neutrophils. <b>2012</b> , 8, 1293-300		12
74	Tolerability and pharmacokinetics of intravitreal sirolimus. <b>2012</b> , 28, 507-14		32
73	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <b>2012</b> , 142, e1S-e111S		37
72	Overexpression of the mammalian target of rapamycin (mTOR) and angiogenesis are poor prognostic factors in early stage NSCLC: a verification study. <b>2012</b> , 75, 217-22		22
71	The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. <b>2012</b> , 13, 81-91		32
70	Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. <b>2012</b> , 12, 2487-97		54
69	Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. <b>2013</b> , 20, 120-3		8
68	Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. <b>2013</b> , 32, 701-6		34
67	A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. <b>2013</b> , 45, 2133-40		14
66	Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. <b>2013</b> , 45, 3325-8		14
65	Everolimus-coated tympanostomy tube on rat tympanic membrane. <b>2013</b> , 77, 1147-51		
64	Topical rapamycin (sirolimus) for facial angiofibromas. <b>2013</b> , 4, 54-7		21
63	Preclinical Evaluation of Coronary Stents: Focus on Safety Issues. <b>2013</b> , 11, 74-99		12

62	The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. <b>2014</b> , 27, 176-86		8
61	Everolimus. <i>Recent Results in Cancer Research</i> , <b>2014</b> , 201, 373-92	1.5	48
60	Is the mTOR-signalling cascade disrupted in Schizophrenia?. <b>2014</b> , 129, 377-87		56
59	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , <b>2014</b> ,	1.5	3
58	Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitro. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2015</b> , 152, 881-8	5.5	26
57	Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2015</b> , 94, 135-40	5.7	13
56	Seguridad y eficacia de nuevos modelos de stents liberadores de sirolimus en el modelo preclínico. <i>Revista Espanola De Cardiologia</i> , <b>2015</b> , 68, 1118-1124	1.5	5
55	Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2015</b> , 68, 1118-24	0.7	1
54	Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. <i>Haematologica</i> , <b>2015</b> , 100, 541-7	6.6	30
53	Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids as mTOR Targeted Anti-cancer Agents. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2016</b> , 64, 346-55	1.9	4
52	Tuberous sclerosis--A model for tumour growth. <i>Seminars in Cell and Developmental Biology</i> , <b>2016</b> , 52, 3-11	7.5	15
51	Fingolimod treatment abrogates chikungunya virus-induced arthralgia. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	33
50	Kinetics studies of the degradation of sirolimus in solid state and in liquid medium. <i>Journal of Thermal Analysis and Calorimetry</i> , <b>2017</b> , 130, 1653-1661	4.1	6
49	Drug release kinetics from a drug-eluting stent with asymmetrical coat. <i>Frontiers in Bioscience - Landmark</i> , <b>2017</b> , 22, 407-415	2.8	5
48	Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets. <i>Pharmaceutics</i> , <b>2018</b> , 10,	6.4	9
47	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , <b>2018</b> ,	1.5	3
46	Everolimus. <i>Recent Results in Cancer Research</i> , <b>2018</b> , 211, 101-123	1.5	30
45	Oceans as a Source of Immunotherapy. <i>Marine Drugs</i> , <b>2019</b> , 17,	6	10

44	Advanced Nanovaccines for Immunotherapy Applications: From Concept to Animal Tests. <b>2019</b> , 231-260		0
43	Clickable, acid labile immunosuppressive prodrugs for in vivo targeting. <i>Biomaterials Science</i> , <b>2020</b> , 8, 266-277	7.4	11
42	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1023-1033	4.9	6
41	Peripheral blood transcriptome identifies high-risk benign and malignant breast lesions. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233713	3.7	7
40	A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28134	3	16
39	Development and Validation of a Bioanalytical LC-MS/MS Method for Simultaneous Determination of Sirolimus in Porcine Whole Blood and Lung Tissue and Pharmacokinetic Application with Coronary Stents. <i>Molecules</i> , <b>2021</b> , 26,	4.8	3
38	Characterizing Immune-Mediated Cytopenias After Allogeneic Hematopoietic Cell Transplantation for Pediatric Nonmalignant Disorders. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 316.e1-316.e8		1
37	What Is Transplant Immunology and Why Are Allografts Rejected?. <b>2010</b> , 25-39		1
36	Study of FK-binding protein: FK506-metabolite complexes by electrospray mass spectrometry: correlation to immunosuppressive activity. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 274-80	3.2	2
35	SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. <i>Transplantation</i> , <b>1997</b> , 64, 36-42	1.8	446
34	Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. <i>Transplantation</i> , <b>1998</b> , 65, 1203-9	1.8	26
33	Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. <i>Transplantation</i> , <b>1998</b> , 65, 1248-55	1.8	26
32	Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. <i>Transplantation</i> , <b>1998</b> , 65, 1584-90	1.8	216
31	Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. <i>Transplantation</i> , <b>1999</b> , 67, 956-62	1.8	33
30	Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. <i>Transplantation</i> , <b>1999</b> , 67, 1036-42	1.8	712
29	Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. <i>Transplantation</i> , <b>1999</b> , 68, 1526-32	1.8	233
28	SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. <i>Transplantation</i> , <b>2000</b> , 69, 497-502	1.8	67
27	Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. <i>Transplantation</i> , <b>2000</b> , 69, 737-42	1.8	51

26	Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. <i>Transplantation</i> , <b>2000</b> , 69, 1252-60	1.8	444
25	Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. <i>Transplantation</i> , <b>2000</b> , 69, 1275-83	1.8	57
24	Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. <i>Transplantation</i> , <b>2002</b> , 73, 915-20	1.8	26
23	Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. <i>Transplantation</i> , <b>2002</b> , 73, 920-5	1.8	112
22	A SYSTEMATIC REVIEW OF MANAGEMENT OF ORAL LICHEN PLANUS. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2016</b> , 5, 1763-1767	0.1	1
21	Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant. <i>World Journal of Transplantation</i> , <b>2015</b> , 5, 19-25	2.3	2
20	Development and validation of an HPLC method for the analysis of sirolimus in drug products. <i>Advanced Pharmaceutical Bulletin</i> , <b>2012</b> , 2, 135-9	4.5	18
19	Neurological Complications of Immunosuppressive Agents. <b>2001</b> , 445-457		
18	Molecular Genetic Screen Design for Agricultural and Pharmaceutical Product Discovery. <i>Drugs and the Pharmaceutical Sciences</i> , <b>2001</b> ,		
17	Rapamycin.		
16	Preclinical Immunotoxicology Assessment of Cytokine Therapeutics. <b>2003</b> , 191-231		
15	TRANSPLANT MEDICINE. <b>2009</b> , 1269-1294		
14	Clinical Pharmacologic Principles and Immunosuppression. <b>2011</b> , 87-109		
13	Rapamycin. <b>1997</b> , 43-51		
12	Current Surgical Management of the Immunocompromised Patient. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , <b>1998</b> , 10, 445-455	3.4	
11	Prophylaxis of renal transplant rejection with new chemical immunosuppressants (tacrolimus, mycophenolate mofetil, sirolimus): will these drugs make antibody induction superfluous?. <i>Current Opinion in Organ Transplantation</i> , <b>1999</b> , 4, 318	2.5	
10	Les nouvelles cibles thérapeutiques. Les nouvelles thérapeutiques ciblées. <b>2006</b> , 233-266		
9	Autres traitements ciblés (trastuzumab exclu). <b>2007</b> , 453-498		

8	[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650]. <i>Chinese Journal of Lung Cancer</i> , <b>2012</b> , 15, 689-93	0.6	1
7	Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art.. <i>Experimental and Clinical Transplantation</i> , <b>2022</b> , 20, 3-9		
6	Engineering of Extracellular Vesicles for Small Molecule-Regulated Cargo Loading and Cytoplasmic Delivery of Bioactive Proteins. <i>Molecular Pharmaceutics</i> ,	5.6	1
5	The SARS-CoV-2 main protease (M pro ): Structure, function, and emerging therapies for COVID-19. <i>MedComm</i> , <b>2022</b> , 3,	2.2	4
4	Comparison of LC-MS/MS and EMIT methods for the precise determination of blood sirolimus in children with vascular anomalies. 13,		1
3	Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I. 13,		0
2	Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients. <b>2023</b> ,		0
1	The Link between Iron Turnover and Pharmacotherapy in Transplant Patients. <b>2023</b> , 15, 1453		0